Rheumatoid arthritis: pathogenesis and therapeutic advances
MedComm · 2024-03 · 5 (3)
DOI: 10.1002/mco2.509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 10.03.2024. Verfasst von Ying Gao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology Changhai Hospital Naval Medical University Shanghai China. Die Arbeit wurde bisher 197-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the unresolved synovial inflammation for tissues‐destructive consequence, which remains one of significant causes of disability and labor loss, affecting about 0.2–1% global population. Although treatments with disease‐modifying antirheumatic drugs (DMARDs) are effective to control inflammation and decrease bone destruction, the overall remission rates of RA still stay at a low level. Therefore, uncovering the pathogenesis of RA and expediting clinical transformation are imminently in need. Here, we summarize the immunological basis, inflammatory pathways, genetic and epigenetic alterations, and metabolic disorders in RA, with highlights on the abnormality of immune cells atlas, epigenetics, and immunometabolism. Besides an overview of first‐line medications including conventional DMARDs, biologics, and small molecule agents, we discuss in depth promising targeted therapies under clinical or preclinical trials, especially epigenetic and metabolic regulators. Additionally, prospects on precision medicine based on synovial biopsy or RNA‐sequencing and cell therapies of mesenchymal stem cells or chimeric antigen receptor T‐cell are also looked forward. The advancements of pathogenesis and innovations of therapies in RA accelerates the progress of RA treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology Changhai Hospital Naval Medical University Shanghai China.
- Naval Medical Center Naval Medical University Shanghai China.
- National Key Laboratory of Immunity & Inflammation Naval Medical University Shanghai China.
- Department of Pathogen Biology Naval Medical University Shanghai China.
ORCID-Profile: Yunkai Zhang, Xingguang Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Gao, Y., Zhang, Y., & Liu, X. (2024). Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm, 5(3). https://doi.org/10.1002/mco2.509
Vancouver
Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm. 2024;5(3). doi:10.1002/mco2.509
BibTeX
@article{Gao2024,
author = {Gao, Ying and Zhang, Yunkai and Liu, Xingguang},
title = {Rheumatoid arthritis: pathogenesis and therapeutic advances},
journal = {MedComm},
year = {2024},
volume = {5},
number = {3},
doi = {10.1002/mco2.509}
}
EUVIMED